Fetal Outcomes After Diabetic Ketoacidosis During Pregnancy

Morrison, Fritha; Movassaghian, Maryam; Seely, Ellen W.; Curran, Ashley; Shubina, Maria; Morton-Eggleston, Emma; Zera, Chloe; Ecker, Jeffrey L.; Brown, F. C.; Turchin, Alexander

doi:10.2337/dc17-0186

Cited by 32 publications

(23 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given that SGLT2 inhibitors are not approved in pregnancy and that DKA during pregnancy is associated with significant maternal and foetal mortality [55,56], dapagliflozin should not be prescribed to females with T1DM who are pregnant or planning pregnancy or who are unwilling to use appropriate contraceptives to avoid pregnancy.…”

Section: Do Not Consider Prescribing Dapagliflozinmentioning

confidence: 99%

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes

et al. 2019

View full text Add to dashboard Cite

Sodium-glucose cotransporter 2 (SGLT2) inhibitor clinical studies in type 1 diabetes mellitus (T1DM) have demonstrated reduced HbA1c and lower glucose variability with increased time in optimal glucose range as well as additional benefits of reductions in weight and insulin dose without increasing the incidence of hypoglycaemia. However, the appropriate use of SGLT2 inhibitor therapies within clinical practise to treat people with T1DM remains unclear. In this article we have used consensus expert opinion alongside the available evidence, product indication and most recent clinical guidance to provide support for the diabetes healthcare community regarding the appropriate use of SGLT2 inhibitors, focussing on specific considerations for appropriate prescribing of dapagliflozin within the T1DM management pathway. Its purpose is to provide awareness of the issues surrounding treatment with dapagliflozin in T1DM as well as offer practical guidance that also includes a checklist tool for appropriate dapagliflozin prescribing. The checklist aims to support clinicians in identifying those people with T1DM most likely to benefit from dapagliflozin treatment as well as situations where caution may be required. Funding: AstraZeneca UK Ltd.

show abstract

Section: Do Not Consider Prescribing Dapagliflozinmentioning

confidence: 99%

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Diabetic ketoacidosis is a well‐recognised medical emergency, and during pregnancy it is potentially fatal for the mother, with estimated maternal mortality of between 4% and 15% . Even in cases of maternal DKA where the mother makes a full recovery, poor outcomes for the fetus can still include stillbirth, preterm birth, and neonatal intensive care unit admissions . A recent retrospective cohort study examining pregnancies complicated by DKA showed that poor patient compliance with the prescribed insulin had been a factor in over half of the cases .…”

Section: Discussionmentioning

confidence: 99%

An unhappy baby helps diagnose maternal diabetic ketoacidosis

2018

View full text Add to dashboard Cite

“…Старостина, 2004]. Частота ДКА в різних регіонах світу в дебюті коливається від 10 до 70 % [10,11]. Вона має значні демографічні та соціально-економічні особливості.…”

Section: вступunclassified

“…А от фахівці з Китаю у хворих їхньої держави встановили приблизно однакову частоту діабетичного кетоацидозу при цукровому діабеті 1 типу (47,9 %) та 2 типу (45,7%), іншу частку склали хворі з атиповим типом ЦД [28]. Cхожу вагому поширеність ДКА серед свого населення з цукровим діабетом 2 типу спостерігають лікарі з Індії [29], лікарі з Малайзії [11]. Велика кількість кетоацидозів також фіксується у хворих з цукровим діабетом 2 типу серед афроамериканців [0,31].…”

Section: вступunclassified

Prevalence of Diabetic Ketoacidosis and Its Etiological Factors in the Podillya Region of Ukraine

Nezhinskaya-Astapenko¹,

Sekret²,

Vlasenkо³

2018

Act. Probl. of the Modern Med.

View full text Add to dashboard Cite

The diabetes mellitus is one of the most common diseases of the world. It is characterized by a large number of complications, including ketoacidosis and its severe form known as ketoacidosis diabetic coma. The aim was to estimate the causes of the development of diabetic ketoacidosis and the duration of treatment of an acute state in different age groups. Materials and methods. The random sampling of patients included 55 individuals with diabetes mellitus admitted to intensive care unit of the Vinnytsia Regional Highly Specialized Endocrinological Center aged from 9 up to 70 years in an emergency condition of diabetic ketoacidosis during 2009-2014. Average age of patients was 31,58 ± 17,18 years. Patients were divided into 3 clinical groups depending on their age. Diagnosis of diabetic ketoacidosis was made on the basis of the order of the Ministry of Public Health of Ukraine No. 254, 27.04.06. The results obtained were statistically processed by the Russian-language "Statistica 6.1" StatSoft, 1995. Results. In the most of the cases (27,2%) the acute condition was caused by improper diet. Insulin therapy disturbance ranked the 2nd place and made up 21,8% of all cases. 20 % of ketoacidosis cases were a disease debut in first diagnosed diabetes mellitus. An average duration of hospital staying ranged from 2,33 to 3,09 days and depended on clinical form of diabetic ketoacidosis. Conclusions. The commonest causes resulting in the emergency of diabetic ketoacidosis were improper diet, non-compliance with insulin therapy, and first diagnosed diabetes mellitus. The duration of the hospital treatment did not depend on age of patients, however considerably differed according to clinical form of diabetic ketoacidosis.

show abstract

Fetal Outcomes After Diabetic Ketoacidosis During Pregnancy

Cited by 32 publications

References 5 publications

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes

An unhappy baby helps diagnose maternal diabetic ketoacidosis

Prevalence of Diabetic Ketoacidosis and Its Etiological Factors in the Podillya Region of Ukraine

Contact Info

Product

Resources

About